Brain distribution of ribavirin after intranasal administration

Antiviral Research

Volumn 92, Issue 3, 2011, Pages 408-414

  Colombo, Gaia ^a   Lorenzini, Luca ^b   Zironi, Elisa ^b   Galligioni, Viola ^b   Sonvico, Fabio ^c   Balducci, Anna Giulia ^a,c   Pagliuca, Giampiero ^b   Giuliani, Alessandro ^b   Calzà, Laura ^b   Scagliarini, Alessandra ^b  

^a UNIVERSITY OF FERRARA   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

^c UNIVERSITY OF PARMA   (Italy)

Author keywords

Blood brain barrier; Nasal delivery; Nose to brain pathway; Ribavirin

Indexed keywords

RIBAVIRIN; ANTIVIRUS AGENT;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BASAL GANGLION; BLOOD BRAIN BARRIER; BODY FLUID; BRAIN CORTEX; BRAIN REGION; CENTRAL NERVOUS SYSTEM; CEREBELLUM; CEREBROSPINAL FLUID; DRUG DIFFUSION; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG PENETRATION; HIPPOCAMPUS; IN VITRO STUDY; IN VIVO STUDY; LIQUID CHROMATOGRAPHY; MALE; NONHUMAN; NOSE MUCOSA; OLFACTORY BULB; POWDER; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RABBIT; RAT; SPRAGUE DAWLEY RAT; STEADY STATE; TANDEM MASS SPECTROMETRY; VIRUS LOAD; ANIMAL; BRAIN; DRUG EFFECT; INTRANASAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; METABOLISM; PERMEABILITY;

ANIMALIA; ORYCTOLAGUS CUNICULUS; RATTUS; RNA VIRUSES;

ADMINISTRATION, INTRANASAL; ANIMALS; ANTIVIRAL AGENTS; BRAIN; INJECTIONS, INTRAVENOUS; MALE; NASAL MUCOSA; PERMEABILITY; RABBITS; RATS; RATS, SPRAGUE-DAWLEY; RIBAVIRIN;

EID: 84858742518     PISSN: 01663542     EISSN: 18729096     Source Type: Journal    
DOI: 10.1016/j.antiviral.2011.09.012     Document Type: Article

References (45)

1. Appel M.J., Summers B.A. Pathogenicity of Morbilliviruses for terrestrial carnivores. Vet. Microbiol. 1995, 44:187-191.
2. Benarroch D., Egloff M.P., Mulard L., Guerreiro C., Romette J.L., Canard B. A structural basis for the inhibition of the NS5 dengue virus mRNA 2'-O-methyltransferase domain by ribavirin 5'-triphosphate. J. Biol. Chem. 2004, 279:35638-35643.
3. Bortolotti F., Balducci A.G., Sonvico F., Russo P., Colombo G. In vitro permeation of desmopressin across rabbit nasal mucosa from liquid nasal sprays: the enhancing effect of potassium sorbate. Eur. J. Pharm. Sci. 2009, 37:36-42.
4. Costantino H.R., Illum L., Brandt G., Johnson P.H., Quay S.C. Intranasal delivery: physicochemical and therapeutic aspects. Int. J. Pharm. 2007, 337:1-24.
5. Crotty S., Cameron C.E., Andino R. RNA virus error catastrophe: direct molecular test by using ribavirin. Proc. Natl. Acad. Sci. USA 2001, 98:6895-6900.
6. Dal Pozzo F., Galligioni V., Vaccari F., Gallina L., Battilani M., Scagliarini A. Antiviral efficacy of EICAR against canine distemper virus (CDV) in vitro. Res. Vet. Sci. 2010, 88:339-344.
7. Danielyan L., Schäfer R., von Ameln-Mayerhofer A., Buadze M., Geisler J., Klopfer T., Burkhardt U., Proksch B., Verleysdonk S., Ayturan M., Buniatian G.H., Gleiter C.H., Frey W.H. Intranasal delivery of cells to the brain. Eur. J. Cell Biol. 2009, 88:315-324.
8. Danielyan L., Schäfer R., von Ameln-Mayerhofer A., Bernhard F., Verleysdonk S., Buadze M., Lourhmati A., Klopfer T., Schaumann F., Schmid B., Koehle C., Proksch B., Weissert R., Reichardt H.M., van den Brandt J., Buniatian G.H., Schwab M., Gleiter C.H., Frey W.H. Therapeutic efficacy of intranasally delivered mesenchymal stem cells in a rat model of Parkinson disease. Rejuvenation Res. 2011, 14:3-16.
9. Dhuria S.V., Hanson L.R., Frey W.H. Intranasal delivery to the central nervous system: mechanisms and experimental considerations. J. Pharm. Sci. 2010, 99:1654-1673.
10. Dyer A.M., Hinchcliffe M., Watts P., Castile J., Jabbal-Gill I., Nankervis R., Smith A., Illum L. Nasal delivery of insulin using novel chitosan based formulations: a comparative study in two animal models between simple chitosan formulations and chitosan nanoparticles. Pharm. Res. 2002, 19:998-1008.
11. Elia G., Belloli C., Cirone F., Lucente M.S., Caruso M., Martella V., Decaro N., Buonavoglia C., Ormas P. In vitro efficacy of ribavirin against canine distemper virus. Antiviral Res. 2008, 77:108-113.
12. Endres C.J., Moss A.M., Ke B., Govindarajan R., Choi D., Messing R.O., Unadkat J.D. The role of the equilibrative nucleoside transporter 1 (ENT1) in transport and metabolism of ribavirin by human and wild-type or ent1(-/-) mouse erythrocytes. J. Pharmacol. Exp. Ther. 2009, 329:387-398.
13. Fang S.H., Hwang L.H., Chen D.S., Chiang B.L. Ribavirin enhancement of hepatitis C virus core antigen-specific type 1 T helper cell response correlates with the increased IL-12 level. J. Hepatol. 2000, 33:791-798.
14. Ferrara E.A., Oishi J.S., Wannemacher R.W., Stephen E.L. Plasma disappearance, urine excretion, and tissue distribution of ribavirin in rats and rhesus monkeys. Antimicrob. Agents Chemother. 1981, 19:1042-1049.
15. Gilbert B.E., Wyde P.R. Pharmacokinetics of ribavirin aerosol in mice. Antimicrob. Agents Chemother. 1988, 32:117-121.
16. Gilbert B.E., Wyde P.R., Wilson S.Z., Robins R.K. Aerosol and intraperitoneal administration of ribavirin and ribavirin triacetate: pharmacokinetics and protection of mice against intracerebral infection with influenza A/WSN virus. Antimicrob. Agents Chemother. 1991, 35:1448-1453.
17. Goswami B.B., Borek E., Sharma O.K., Fujitaki J., Smith R.A. The broad spectrum antiviral agent ribavirin inhibits capping of mRNA. Biochem. Biophys. Res. Commun. 1979, 89:830-836.
18. Griot C., Vandevelde M., Schobesberger M., Zurbriggen A. Canine distemper, a re-emerging morbillivirus with complex neuropathogenic mechanisms. Anim. Health Res. Rev. 2003, 4:1-10.
19. Han L.Y., Wilson R., Slater S., Rutman A., Read R.C., Snell N.J., Cole P.J. In vitro and in vivo effects of ribavirin on human respiratory epithelium. Thorax 1990, 45:100-104.
20. Hanson L.R., Roeytenberg A., Martinez P.M., Coppes V.G., Sweet D.C., Rao R.J., Marti D.L., Hoekman J.D., Matthews R.B., Frey W.H., Panter S.S. Intranasal deferoxamine provides increased brain exposure and significant protection in rat ischemic stroke. J. Pharmacol. Exp. Ther. 2009, 330:679-686.
21. Hosoya M., Mori S., Tomoda A., Mori K., Sawaishi Y., Kimura H., Shigeta S., Suzuki H. Pharmacokinetics and effects of ribavirin following intraventricular administration for treatment of subacute sclerosing panencephalitis. Antimicrob. Agents Chemother. 2004, 48:4631-4635.
22. Illum L. Is nose-to-brain transport of drugs in man a reality?. J. Pharm. Pharmacol. 2004, 56:3-17.
23. Illum L., Davis S.S., Pawula M., Fisher A.N., Barrett D.A., Farraj N.F., Shaw P.N. Nasal administration of morphine-6-glucuronide in sheep - a pharmacokinetic study. Biopharm. Drug Dispos. 1996, 17:717-724.
24. Jeulin H., Grancher N., Kedzierewicz F., Finance C., Le Faou A.E., Venard V. In vivo antiviral activity of ribavirin/alpha-cyclodextrin complex: evaluation on experimental measles virus encephalitis in mice. Int. J. Pharm. 2008, 357:148-153.
25. Jeulin H., Venard V., Carapito D., Finance C., Kedzierewicz F. Effective ribavirin concentration in mice brain using cyclodextrin as a drug carrier: evaluation in a measles encephalitis model. Antiviral Res. 2009, 81:261-266.
26. Leyssen P., Balzarini J., De Clercq E., Neyts J. The predominant mechanism by which ribavirin exerts its antiviral activity in vitro against flaviviruses and paramyxoviruses is mediated by inhibition of IMP dehydrogenase. J. Virol. 2005, 79:1943-1947.
27. Liu X., Testa B., Fahr A. Lipophilicity and its relationship with passive drug permeation. Pharm. Res. 2011, 28:962-977.
28. Livonesi M.C., De Sousa R.L., Badra S.J., Figueiredo L.T. In vitro and in vivo studies of ribavirin action on Brazilian Orthobunyavirus. Am. J. Trop. Med. Hyg. 2006, 75:1011-1016.
29. Maag D., Castro C., Hong Z., Cameron C.E. Hepatitis C virus RNA-dependent RNA polymerase (NS5B) as a mediator of the antiviral activity of ribavirin. J. Biol. Chem. 2001, 276:46094-46098.
30. Merkus F.W., Verhoef J.C., Schipper N.G., Marttin E. Nasal mucociliary clearance as a factor in nasal drug delivery. Adv. Drug Deliv. Rev. 1998, 29:13-38.
31. Morse G.D., Shelton M.J., O'Donnell A.M. Comparative pharmacokinetics of antiviral nucleoside analogues. Clin. Pharmacokinet. 1993, 24:101-123.
32. Patterson J.L., Fernandez-Larsson R. Molecular mechanisms of action of ribavirin. Rev. Infect. Dis. 1990, 12:1139-1146.
33. Riner A., Chan-Tack K.M., Murray J.S. Original research: intravenous ribavirin - review of the FDA's Emergency Investigational New Drug Database (1997-2008) and literature review. Postgrad. Med. 2009, 121:139-146.
34. Rockx B., Bossart K.N., Feldmann F., Geisbert J.B., Hickey A.C., Brining D., Callison J., Safronetz D., Marzi A., Kercher L., Long D., Broder C.C., Feldmann H., Geisbert T.W. A novel model of lethal Hendra virus infection in African green monkeys and the effectiveness of ribavirin treatment. J. Virol. 2010, 84:9831-9839.
35. Rudd P.A., Bastien-Hamel L.E., von Messling V. Acute canine distemper encephalitis is associated with rapid neuronal loss and local immune activation. J. Gen. Virol. 2010, 91:980-989.
36. Russo P., Sacchetti C., Pasquali I., Bettini R., Massimo G., Colombo P., Rossi A. Primary microparticles and agglomerates of morphine for nasal insufflation. J. Pharm. Sci. 2006, 95:2553-2561.
37. Scagliarini A., Vaccari F., Gallina L., Dal Pozzo F., Prosperi S. In vitro evaluation of antiviral activity of ribavirin against canine distemper virus. Vet. Res. Commun. 2006, 30:269-272.
38. Singethan K., Hiltensperger G., Kendl S., Wohlfahrt J., Plattet P., Holzgrabe U., Schneider-Schaulies J. N-(3-Cyanophenyl)-2-phenylacetamide, an effective inhibitor of morbillivirus-induced membrane fusion with low cytotoxicity. J. Gen. Virol. 2010, 91:2762-2772.
39. Sips G.J., Chesik D., Glazenburg L., Wilschut J., De Keyser J., Wilczak N. Involvement of Morbilliviruses in the pathogenesis of demyelinating disease. Rev. Med. Virol. 2007, 17:223-244.
40. Strazielle N., Ghersi-Egea J.F. Factors affecting delivery of antiviral drugs to the brain. Rev. Med. Virol. 2005, 15:105-133.
41. Thorne R.G., Frey W.H. Delivery of neurotrophic factors to the central nervous system: pharmacokinetic considerations. Clin. Pharmacokinet. 2001, 40:907-946.
42. Vidgren M.T., Kublik H. Nasal delivery systems and their effect on deposition and absorption. Adv. Drug Deliv. Rev. 1998, 29:157-177.
43. Xiang J., Fang X., Li X. Transbuccal delivery of 2',3'-dideoxycytidine: in vitro permeation study and histological investigation. Int. J. Pharm. 2002, 231:57-66.
44. Yang J.P., Liu H.J., Cheng S.M., Wang Z.L., Cheng X., Yu H.X., Liu X.F. Direct transport of VEGF from the nasal cavity to brain. Neurosci. Lett. 2009, 449:108-111.
45. Zironi E., Gazzotti T., Lugoboni B., Barbarossa A., Scagliarini A., Pagliuca G. Development of a rapid LC-MS/MS method for ribavirin determination in rat brain. J. Pharm. Biomed. Anal. 2011, 54:889-892.